MA hails drugs ac­cess

Pharmacy Daily - - NEWS -

PEAK in­no­va­tor medicines rep­re­sen­ta­tives group Medicines Aus­tralia (MA) has wel­comed the govern­ment’s re­sponse to the Se­nate Com­mu­nity Af­fairs Ref­er­ences Com­mit­tee Re­port: ‘Avail­abil­ity of new, in­no­va­tive and spe­cial­ist can­cer drugs in Aus­tralia’.

The re­port rec­om­mended im­prove­ments to and stream­lin­ing of ex­ist­ing reg­u­la­tory and as­sess­ment pro­cesses for new medicines, with many of the is­sues cur­rently be­ing ad­dressed through re­forms of the Ther­a­peu­tic Goods Ad­min­is­tra­tion (TGA).

“In par­tic­u­lar, we look for­ward to the pas­sage of leg­is­la­tion cur­rently be­fore Par­lia­ment that in­cludes pro­vi­sions for another ex­pe­dited path­way called Pro­vi­sional Ap­proval that aims to speed up ac­cess to new medicines,” MA said.

“Not only does the Agree­ment pro­vide Ψ1.8 bil­lion in sav­ings on PBS listed medicines that will be used to pay for new treat­ments, the Govern­ment has com­mit­ted to re­form that will im­prove and ac­cel­er­ate pro­cesses that lead to a medicine be­ing made avail­able on the PBS,” the or­gan­i­sa­tion added. dark par­ti­cles of sil­ica.

It’s pre­sumed the par­ti­cles have been re­leased from the dessi­cant cylin­der that is placed in­side the bot­tle to en­sure the con­tents are kept dry.

The par­ti­cles may be large enough to see as small specks, or sim­ply ap­pear as a dust that dis­colours the tablets and\or the in­side of the bot­tle.

The po­ten­tial con­tam­i­na­tion is clas­si­fied as a qual­ity de­fect and is not con­sid­ered to im­pact prod­uct safety or ef­fi­cacy.

Con­sumers are be­ing ad­vised to check the batch num­ber and if it is from an af­fected batch, re­turn it to a phar­macy for a re­fund or re­place­ment.

Health prob­lems are un­likely to be ex­pe­ri­enced as a re­sult of the is­sue, the TGA said - more in­for­ma­tion at

Newspapers in English

Newspapers from Australia

© PressReader. All rights reserved.